Clinical Trials Logo
  1. Home
  2. Wiskott-Aldrich Syndrome
  3. NCT00004341

Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders

Wiskott-Aldrich Syndrome Clinical Trial

Clinical Trial Summary

OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders.

II. Explore the mutations within each syndrome to better understand the genetics of these disorders.

III. Study the function of the Wiskott-Aldrich syndrome proteins (WASP). IV. Design methods to identify carriers and for prenatal diagnosis. V. Explore new avenues for therapy.

Clinical Trial Description

PROTOCOL OUTLINE: Patients are studied systematically to determine the extent of their immune deficiency and to confirm a specific diagnosis. Patients with a known immunodeficiency syndrome are studied in detail to identify the gene mutation, to assess the effect of the mutation on the gene product, and to establish cell lines for further in vitro assessment of the genetic defect. The function of Wiskott-Aldrich syndrome proteins (WASP) in hematopoietic cells is studied.

Family members of patients with X-linked disorders are studied to identify carrier females. ;

Study Design

Primary Purpose: Screening

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00004341
Study type Observational
Source Office of Rare Diseases (ORD)
Contact
Status Active, not recruiting
Phase N/A
Start date July 1995
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT01953016 - Participation in a Research Registry for Immune Disorders
Active, not recruiting NCT02333760 - Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Phase 1/Phase 2
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT04371939 - Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome Phase 2
Completed NCT01347346 - Gene Therapy for WAS Phase 1/Phase 2
Completed NCT00160355 - Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Phase 1
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT01347242 - Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Phase 1/Phase 2
Completed NCT01289847 - A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Phase 4
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Enrolling by invitation NCT03198195 - Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome N/A
Recruiting NCT03019809 - A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Phase 2
Terminated NCT00909363 - Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Phase 2
Enrolling by invitation NCT01852370 - Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Phase 1/Phase 2
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Active, not recruiting NCT01410825 - Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Phase 1/Phase 2
Completed NCT03399461 - Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
Active, not recruiting NCT03837483 - A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome Phase 3